Perspective · 10 Sep 2026
Conference abstractPublished 22 Oct 2012
Establishment of allogeneic mixed chimerism using bone marrow cells engineered to display on their surface an exogenous FasL protein with potent apoptotic activity
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Bone marrow transplantation (BMT) as a source of hematopoietic stem cells is perceived as a powerful therapeutic regimen that can potentially treat a variety of inherited and acquired diseases. BMT leading to mixed allogeneic hematopoietic chimerism (MAC) can be used as an immunomodulatory approach to induce tolerance to auto-, allo-, and xeno-antigens for the treatment of autoimmune disorders and prevention of foreign graft rejection. Mixed chimeras are tolerant to both donor and host antigens since i) stem cells in the donor BM give rise to immune cells, such as lymphocytes, that are ?educated? in the host immune environment for nonresponsiveness to the host antigens and ii) macrophages and dendritic cells arising from the donor bone marrow serve as antigen-presenting cells in the thymus to eliminate donor reactive host lymphocytes. However, BMT requires conditioning of recipients for effective engraftment and conditioning regimens used to establish MAHC in the clinic are often toxic. The development of nontoxic and effective approaches to induce MAHC in the clinic, therefore, is of great scientific and therapeutic pursuit. Towards this end, we have recently developed a novel approach, called ProtEx?, that allows us effective and rapid engineering of bone marrow cells (BMCs) to display on their surface a modified apoptotic form of FasL protein. Transplantation of these ?engineered? cells into allogeneic hosts was effective in establishing MAHC in recipients with minimal conditioning and resulted in durable tolerance to donor grafts. Furthermore, this approach resulted in prevention of graft-vs-host disease (GVHD), a major complication of BMT, by effectively eliminating mature T cells via apoptosis in the transplanted BMCs. Engineering of total BMCs with exogenous immunomodulatory proteins serves as an effective, rapid, and clinically applicable approach for the establishment of MAHC with significant clinical transplantation implications.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Esma S. Yolcu”
